B
B. Findlay
Researcher at McMaster University
Publications - 48
Citations - 13722
B. Findlay is an academic researcher from McMaster University. The author has contributed to research in topics: Oxaliplatin & Chemotherapy. The author has an hindex of 26, co-authored 42 publications receiving 11071 citations. Previous affiliations of B. Findlay include Harvard University & Hotel Dieu Hospital.
Papers
More filters
Journal ArticleDOI
Erlotinib in previously treated non-small-cell lung cancer.
Frances A. Shepherd,José Rodrigues Pereira,Tudor Ciuleanu,Eng Huat Tan,Vera Hirsh,Sumitra Thongprasert,Daniel Campos,Savitree Maoleekoonpiroj,Michael Smylie,Renato G. Martins,Maximiliano Van Kooten,Mircea Dediu,B. Findlay,Dongsheng Tu,Dianne Johnston,Andrea Bezjak,Gary M. Clark,Pedro Santabárbara,Lesley Seymour +18 more
TL;DR: Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
Journal ArticleDOI
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
Richard M. Goldberg,Daniel J. Sargent,Roscoe F. Morton,Charles S. Fuchs,Ramesh K. Ramanathan,Stephen K. Williamson,B. Findlay,Henry C. Pitot,Steven R. Alberts +8 more
TL;DR: The FOLFOX regimen of oxaliplatin and infused fluorouracil plus leucovorin was active and comparatively safe and should be considered as a standard therapy for patients with advanced colorectal cancer.
Journal ArticleDOI
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
Richard M. Goldberg,Daniel J. Sargent,Roscoe F. Morton,Charles S. Fuchs,Ramesh K. Ramanathan,Stephen K. Williamson,B. Findlay,Henry C. Pitot,Steven R. Alberts +8 more
TL;DR: The FOLFOX regimen of oxaliplatin and infused fluorouracil plus leucovorin was active and comparatively safe and should be considered as a standard therapy for patients with advanced colorectal cancer.
Journal ArticleDOI
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Mark Levine,Vivien H.C. Bramwell,Kathleen I. Pritchard,B. Norris,Lois E. Shepherd,H. Abu-Zahra,B. Findlay,David Warr,David Bowman,J. Myles,Andrew Arnold,T. Vandenberg,R. MacKenzie,J. Robert,J. Ottaway,Margot J. Burnell,C. K. Williams,Dongsheng Tu +17 more
TL;DR: The results of this trial show the superiority of CEF over CMF in terms of both disease-free and overall survival in premenopausal women with axillary node-positive breast cancer.
Journal ArticleDOI
Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10
Charles A. Butts,Keyue Ding,Lesley Seymour,Philip Twumasi-Ankrah,Barbara Graham,David R. Gandara,David H. Johnson,Kenneth A. Kesler,Mark A. Green,Mark Vincent,Yvon Cormier,Glenwood D. Goss,B. Findlay,Michael R. Johnston,Ming-Sound Tsao,Frances A. Shepherd +15 more
TL;DR: Prolonged follow-up of patients from the JBR10 trial continues to show a benefit in survival for adjuvant chemotherapy, and this benefit appears to be confined to N1 patients.